Cuba's Center for Genetic Engineering and Biotechnology (CIGB) has registered the first recombinant monoclonal antibody to be used in the production of an anti-hepatitis B vaccine.
CIGB Deputy Director General Carlos Borroto described it as a true world scientific breakthrough, and it was obtained after having completed all necessary stages of the technological process required for it.
At a press conference in Havana, Borroto said it was the result of research work similar to what is being developed by research teams from dozens of highly developed nations.
Baptized as CB-Hep.1, the recombinant monoclonal antibody made of plants is of great relevance to increase the production of the anti-hepatitis B vaccine at a lower cost.
From the research point of view, this breakthrough leaves a door opened to obtain other effective antibodies to fight illnesses, including cancer.